New obesity drug from Lilly delivers major weight loss
Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a Phase 3 clinical trial, as well as key secondary end points for obesity, delivering clinically meaningful weight loss. The highest dose of retatrutide helped patients lose 28.3 percent of their weight from baseline— or 70.3 pounds — on average over 80 weeks, compared with 2.2 percent with placebo. The results evaluated only the patients who stayed on the drug.
- ▪Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a Phase 3 clinical trial, as well as key secondary end points for obesity, delivering clinically meaningful weight loss.
- ▪The highest dose of retatrutide helped patients lose 28.3 percent of their weight from baseline— or 70.3 pounds — on average over 80 weeks, compared with 2.2 percent with placebo.
- ▪The results evaluated only the patients who stayed on the drug.
6 outlets in our directory ran this story, first to last over 8 hours. Coverage spans 3 points on the political spectrum — 1 lean left, 3 centre, 1 right.
- ▪ New Eli Lilly weight loss drug has dramatic effects in clinical trial — Washington Examiner
- ▪ A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says — TIME — Top
- ▪ Eli Lilly's next-generation weight loss injection posted record results in obesity trial — Quartz
- ▪ New Weight Loss Drug Retatrutide Delivers Stunning Results — TODAY.com
- ▪ Eli Lilly says next-generation weight loss drug clears crucial obesity trial — US Top News and Analysis
The Hill files mainly under politics. We currently carry 1,451 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Hill |
| Canonical URL | https://thehill.com/policy/healthcare/5889665-eli-lilly-new-obesity-drug-weight-loss/ |
| Publication time | Thu, 21 May 2026 19:04:37 +0000 |
| Retrieval time | 2026-05-21T19:11:35.680Z |
| Last seen | 2026-05-21T19:11:37.327Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | aBS1rBimYei- · 6 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Healthcare New obesity drug from Lilly delivers major weight loss Comments: by Nathaniel Weixel - 05/21/26 3:04 PM ET Comments: Link copied by Nathaniel Weixel - 05/21/26 3:04 PM ET Comments: Link copied NOW PLAYING An investigational obesity drug from Eli Lilly cleared important end points in a late-stage trial, the company said Thursday, by helping patients lose up to 30 percent of their body weight. Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a Phase 3 clinical trial, as well as key secondary end points for obesity, delivering clinically meaningful weight loss. The highest dose of retatrutide helped patients lose 28.3 percent of their weight from baseline— or 70.3 pounds — on average over 80 weeks, compared with 2.2 percent with placebo.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hill.